Glaucoma as a neuropathy amenable to neuroprotection and immune manipulation

Progress in Brain Research

Volumn 173, Issue , 2008, Pages 375-384

  Schwartz, Michal ^a   London, Anat ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

glaucoma; monocytes; neurodegenerative diseases; neuroprotection; optic neuropathy; protective autoimmunity; secondary degeneration; therapeutic vaccination

Indexed keywords

CALCIUM; FREE RADICAL; GLATIRAMER; GLUTAMIC ACID; GROWTH FACTOR; MEMANTINE; NEUROTROPHIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; BLINDNESS; CELL DEATH; CELL LOSS; DEGENERATIVE DISEASE; EXCITOTOXICITY; GLAUCOMA; IMMUNITY; NEUROPATHY; NEUROPROTECTION; NONHUMAN; OPTIC NERVE; OPTIC NERVE DISEASE; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; RETINA GANGLION CELL; REVIEW; T LYMPHOCYTE; VISUAL FIELD; VISUAL IMPAIRMENT;

ANTIGENS; CALCIUM; FREE RADICALS; GLAUCOMA; GLUTAMIC ACID; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTRAOCULAR PRESSURE; NEUROPROTECTIVE AGENTS; OPTIC NERVE DISEASES; OXIDATIVE STRESS; RETINAL GANGLION CELLS; RISK FACTORS;

EID: 53049109849     PISSN: 00796123     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0079-6123(08)01126-6     Document Type: Review

References (95)

1. Abe K., Pan L.H., Watanabe M., Kato T., and Itoyama Y. Induction of nitrotyrosine-like immunoreactivity in the lower motor neuron of amyotrophic lateral sclerosis. Neurosci. Lett. 199 (1995) 152-154
2. Andersen J.K. Oxidative stress in neurodegeneration: cause or consequence?. Nat. Med. 10 Suppl (2004) S18-S25
3. Avidan H., Kipnis J., Butovsky O., Caspi R.R., and Schwartz M. Vaccination with autoantigen protects against aggregated beta-amyloid and glutamate toxicity by controlling microglia: effect of CD4+CD25+ T cells. Eur. J. Immunol. 34 (2004) 3434-3445
4. Bakalash S., Kessler A., Mizrahi T., Nussenblatt R., and Schwartz M. Antigenic specificity of immunoprotective therapeutic vaccination for glaucoma. Invest. Ophthalmol. Vis. Sci. 44 (2003) 3374-3381
5. Bakalash S., Kipnis J., Yoles E., and Schwartz M. Resistance of retinal ganglion cells to an increase in intraocular pressure is immune-dependent. Invest. Ophthalmol. Vis. Sci. 43 (2002) 2648-2653
6. Bakalash S., Shlomo G.B., Aloni E., Shaked I., Wheeler L., Ofri R., and Schwartz M. T-cell-based vaccination for morphological and functional neuroprotection in a rat model of chronically elevated intraocular pressure. J. Mol. Med. 83 (2005) 904-916
7. Barouch R., and Schwartz M. Autoreactive T cells induce neurotrophin production by immune and neural cells in injured rat optic nerve: Implications for protective autoimmunity. FASEB J. 16 (2002) 1304-1306
8. 2+ channels and in gerbil global cerebral ischaemia. Eur. J. Pharmacol. 299 (1996) 103-112
9. Beal M.F. Excitotoxicity and nitric oxide in Parkinson's disease pathogenesis. Ann. Neurol. 44 (1998) S110-S114
10. Beckman J.S., Carson M., Smith C.D., and Koppenol W.H. ALS, SOD and peroxynitrite. Nature 364 (1993) 584
11. Benner E.J., Mosley R.L., Destache C.J., Lewis T.B., Jackson-Lewis V., Gorantla S., Nemachek C., Green S.R., Przedborski S., and Gendelman H.E. Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 9435-9440
12. Blair M., Pease M.E., Hammond J., Valenta D., Kielczewski J., Levkovitch-Verbin H., and Quigley H. Effect of glatiramer acetate on primary and secondary degeneration of retinal ganglion cells in the rat. Invest. Ophthalmol. Vis. Sci. 46 (2005) 884-890
13. Brubaker R.F. Delayed functional loss in glaucoma. LII Edward Jackson Memorial Lecture. Am. J. Ophthalmol. 121 (1996) 473-483
14. Burgoyne C.F., Downs J.C., Bellezza A.J., Suh J.K., and Hart R.T. The optic nerve head as a biomechanical structure: a new paradigm for understanding the role of IOP-related stress and strain in the pathophysiology of glaucomatous optic nerve head damage. Prog. Retin. Eye Res. 24 (2005) 39-73
15. Butovsky O., Hauben E., and Schwartz M. Morphological aspects of spinal cord autoimmune neuroprotection: colocalization of T cells with B7-2 (CD86) and prevention of cyst formation. FASEB J. 15 (2001) 1065-1067
16. Butovsky O., Talpalar A.E., Ben-Yaakov K., and Schwartz M. Activation of microglia by aggregated beta-amyloid or lipopolysaccharide impairs MHC-II expression and renders them cytotoxic whereas IFN-gamma and IL-4 render them protective. Mol. Cell. Neurosci. 29 (2005) 381-393
17. Castegna A., Thongboonkerd V., Klein J.B., Lynn B., Markesbery W.R., and Butterfield D.A. Proteomic identification of nitrated proteins in Alzheimer's disease brain. J. Neurochem. 85 (2003) 1394-1401
18. Chauhan B.C., and Drance S.M. The relationship between intraocular pressure and visual field progression in glaucoma. Graefes Arch. Clin. Exp. Ophthalmol. 230 (1992) 521-526
19. Chidlow G., Wood J.P., and Casson R.J. Pharmacological neuroprotection for glaucoma. Drugs 67 (2007) 725-759
20. Choi D.W. Calcium-mediated neurotoxicity: relationship to specific channel types and role in ischemic damage. Trends Neurosci. 11 (1988) 465-469
21. Choi D.W. Glutamate neurotoxicity and diseases of the nervous system. Neuron 1 (1988) 623-634
22. Dreyer E.B. A proposed role for excitotoxicity in glaucoma. J. Glaucoma 7 (1998) 62-67
23. Fisher J., Levkovitch-Verbin H., Schori H., Yoles E., Butovsky O., Kaye J.F., Ben-Nun A., and Schwartz M. Vaccination for neuroprotection in the mouse optic nerve: implications for optic neuropathies. J. Neurosci. 21 (2001) 136-142
24. Gao H., Qiao X., Hefti F., Hollyfield J.G., and Knusel B. Elevated mRNA expression of brain-derived neurotrophic factor in retinal ganglion cell layer after optic nerve injury. Invest. Ophthalmol. Vis. Sci. 38 (1997) 1840-1847
25. Giasson B.I., Duda J.E., Murray I.V., Chen Q., Souza J.M., Hurtig H.I., Ischiropoulos H., Trojanowski J.Q., and Lee V.M. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 290 (2000) 985-989
26. Gupta N., and Yucel Y.H. Glaucoma as a neurodegenerative disease. Curr. Opin. Ophthalmol. 18 (2007) 110-114
27. Hartwick A.T. Beyond intraocular pressure: neuroprotective strategies for future glaucoma therapy. Optom. Vis. Sci. 78 (2001) 85-94
28. Hauben E., Agranov E., Gothilf A., Nevo U., Cohen A., Smirnov I., Steinman L., and Schwartz M. Posttraumatic therapeutic vaccination with modified myelin self-antigen prevents complete paralysis while avoiding autoimmune disease. J. Clin. Invest. 108 (2001) 591-599
29. Heijl A., Leske M.C., Bengtsson B., Hyman L., Bengtsson B., and Hussein M. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch. Ophthalmol. 120 (2002) 1268-1279
30. Jay J.L., and Allan D. The benefit of early trabeculectomy versus conventional management in primary open angle glaucoma relative to severity of disease. Eye 3 Pt 5 (1989) 528-535
31. Johnson E.C., Cepurna W.O., Jia L., and Morrison J.C. The use of cyclodialysis to limit exposure to elevated intraocular pressure in rat glaucoma models. Exp. Eye Res. 83 (2006) 51-60
32. Kass M.A., Heuer D.K., Higginbotham E.J., Johnson C.A., Keltner J.L., Miller J.P., Parrish II R.K., Wilson M.R., and Gordon M.O. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch. Ophthalmol. 120 (2002) 701-713 discussion 829-730
33. Kipnis J., Cardon M., Avidan H., Lewitus G.M., Mordechay S., Rolls A., Shani Y., and Schwartz M. Dopamine, through the extracellular signal-regulated kinase pathway, downregulates CD4+CD25+ regulatory T-cell activity: implications for neurodegeneration. J. Neurosci. 24 (2004) 6133-6143
34. Kipnis J., Mizrahi T., Hauben E., Shaked I., Shevach E., and Schwartz M. Neuroprotective autoimmunity: Naturally occurring CD4+CD25+ regulatory T cells suppress the ability to withstand injury to the central nervous system. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 15620-15625
35. Kipnis J., Yoles E., Porat Z., Cohen A., Mor F., Sela M., Cohen I.R., and Schwartz M. T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 7446-7451
36. Klocker N., Cellerino A., and Bahr M. Free radical scavenging and inhibition of nitric oxide synthase potentiates the neurotrophic effects of brain-derived neurotrophic factor on axotomized retinal ganglion cells in vivo. J. Neurosci. 18 (1998) 1038-1046
37. Lancelot E., and Beal M.F. Glutamate toxicity in chronic neurodegenerative disease. Prog. Brain Res. 116 (1998) 331-347
38. Lansbury P.T., and Lashuel H.A. A century-old debate on protein aggregation and neurodegeneration enters the clinic. Nature 443 (2006) 774-779
39. Leske M.C., Heijl A., Hussein M., Bengtsson B., Hyman L., and Komaroff E. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch. Ophthalmol. 121 (2003) 48-56
40. Levin L.A., Schlamp C.L., Spieldoch R.L., Geszvain K.M., and Nickells R.W. Identification of the bcl-2 family of genes in the rat retina. Invest. Ophthalmol. Vis. Sci. 38 (1997) 2545-2553
41. Levkovitch-Verbin H., Harris-Cerruti C., Groner Y., Wheeler L.A., Schwartz M., and Yoles E. RGC death in mice after optic nerve crush injury: oxidative stress and neuroprotection. Invest. Ophthalmol. Vis. Sci. 41 (2000) 4169-4174
42. Lipton S.A. Pathologically-activated therapeutics for neuroprotection: mechanism of NMDA receptor block by memantine and S-nitrosylation. Curr. Drug Targets 8 (2007) 621-632
43. Lipton S.A., and Rosenberg P.A. Excitatory amino acids as a final common pathway for neurologic disorders. N. Engl. J. Med. 330 (1994) 613-622
44. Mansour-Robaey S., Clarke D.B., Wang Y.C., Bray G.M., and Aguayo A.J. Effects of ocular injury and administration of brain-derived neurotrophic factor on survival and regrowth of axotomized retinal ganglion cells. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 1632-1636
45. Martindale J.L., and Holbrook N.J. Cellular response to oxidative stress: signaling for suicide and survival. J. Cell Physiol. 192 (2002) 1-15
46. McKinnon S.J., Lehman D.M., Kerrigan-Baumrind L.A., Merges C.A., Pease M.E., Kerrigan D.F., Ransom N.L., Tahzib N.G., Reitsamer H.A., Levkovitch-Verbin H., Quigley H.A., and Zack D.J. Caspase activation and amyloid precursor protein cleavage in rat ocular hypertension. Invest. Ophthalmol. Vis. Sci. 43 (2002) 1077-1087
47. Mizrahi T., Hauben E., and Schwartz M. The tissue-specific self-pathogen is the protective self-antigen: the case of uveitis. J. Immunol. 169 (2002) 5971-5977
48. Moalem G., Gdalyahu A., Shani Y., Otten U., Lazarovici P., Cohen I.R., and Schwartz M. Production of neurotrophins by activated T cells: implications for neuroprotective autoimmunity. J. Autoimmun. 15 (2000) 331-345
49. Moalem G., Leibowitz-Amit R., Yoles E., Mor F., Cohen I.R., and Schwartz M. Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy. Nat. Med. 5 (1999) 49-55
50. Mozaffarieh M., and Flammer J. Is there more to glaucoma treatment than lowering IOP?. Surv. Ophthalmol. 52 Suppl 2 (2007) S174-S179
51. Napper G.A., Pianta M.J., and Kalloniatis M. Reduced glutamate uptake by retinal glial cells under ischemic/hypoxic conditions. Vis. Neurosci. 16 (1999) 149-158
52. Neufeld A.H., Sawada A., and Becker B. Inhibition of nitric-oxide synthase 2 by aminoguanidine provides neuroprotection of retinal ganglion cells in a rat model of chronic glaucoma. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 9944-9948
53. Nickells R.W. From ocular hypertension to ganglion cell death: a theoretical sequence of events leading to glaucoma. Can. J. Ophthalmol. 42 (2007) 278-287
54. Nickells R.W., Schlamp C.L., Li Y., Kaufman P.L., Heatley G., Peterson J.C., Faha B., and VerHoeve J.N. Surgical lowering of elevated intraocular pressure in monkeys prevents progression of glaucomatous disease. Exp. Eye Res. 84 (2007) 729-736
55. Nouri-Mahdavi K., Brigatti L., Weitzman M., and Caprioli J. Outcomes of trabeculectomy for primary open-angle glaucoma. Ophthalmology 102 (1995) 1760-1769
56. Oku H., Yamaguchi H., Sugiyama T., Kojima S., Ota M., and Azuma I. Retinal toxicity of nitric oxide released by administration of a nitric oxide donor in the albino rabbit. Invest. Ophthalmol. Vis. Sci. 38 (1997) 2540-2544
57. Olney J.W. Glutaate-induced retinal degeneration in neonatal mice. Electron microscopy of the acutely evolving lesion. J. Neuropathol. Exp. Neurol. 28 (1969) 455-474
58. Olney J.W., Price M.T., Samson L., and Labruyere J. The role of specific ions in glutamate neurotoxicity. Neurosci. Lett. 65 (1986) 65-71
59. Oltvai Z.N., and Korsmeyer S.J. Checkpoints of dueling dimers foil death wishes. Cell 79 (1994) 189-192
60. Peinado-Ramon P., Salvador M., Villegas-Perez M.P., and Vidal-Sanz M. Effects of axotomy and intraocular administration of NT-4, NT-3, and brain-derived neurotrophic factor on the survival of adult rat retinal ganglion cells. A quantitative in vivo study. Invest. Ophthalmol. Vis. Sci. 37 (1996) 489-500
61. Potashkin J.A., and Meredith G.E. The role of oxidative stress in the dysregulation of gene expression and protein metabolism in neurodegenerative disease. Antioxid. Redox Signal. 8 (2006) 144-151
62. Quigley H.A. Neuronal death in glaucoma. Prog. Retin. Eye Res. 18 (1999) 39-57
63. Quigley H.A., and Maumenee A.E. Long-term follow-up of treated open-angle glaucoma. Am. J. Ophthalmol. 87 (1979) 519-525
64. Richler M., Werner E.B., and Thomas D. Risk factors for progression of visual field defects in medically treated patients with glaucoma. Can. J. Ophthalmol. 17 (1982) 245-248
65. Riederer P., and Hoyer S. From benefit to damage. Glutamate and advanced glycation end products in Alzheimer brain. J. Neural Transm. 113 (2006) 1671-1677
66. Ritch R. Potential role for Ginkgo biloba extract in the treatment of glaucoma. Med. Hypotheses 54 (2000) 221-235
67. Rocha M., Martins R.A., and Linden R. Activation of NMDA receptors protects against glutamate neurotoxicity in the retina: evidence for the involvement of neurotrophins. Brain Res. 827 (1999) 79-92
68. Sahai S. Glutamate in the mammalian CNS. Eur. Arch. Psychiatry Clin. Neurosci. 240 (1990) 121-133
69. Schori H., Kipnis J., Yoles E., WoldeMussie E., Ruiz G., Wheeler L.A., and Schwartz M. Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: implications for glaucoma. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 3398-3403
70. Schulzer M., Drance S.M., Carter C.J., Brooks D.E., Douglas G.R., and Lau W. Biostatistical evidence for two distinct chronic open angle glaucoma populations. Br. J. Ophthalmol. 74 (1990) 196-200
71. Schwartz M. Neurodegeneration and neuroprotection in glaucoma: development of a therapeutic neuroprotective vaccine: the Friedenwald lecture. Invest. Ophthalmol. Vis. Sci. 44 (2003) 1407-1411
72. Schwartz M. Lessons for glaucoma from other neurodegenerative diseases: can one treatment suit them all?. J. Glaucoma 14 (2005) 321-323
73. Schwartz M. Modulating the immune system: a vaccine for glaucoma?. Can. J. Ophthalmol. 42 (2007) 439-441
74. Schwartz M., Belkin M., Yoles E., and Solomon A. Potential treatment modalities for glaucomatous neuropathy: neuroprotection and neuroregeneration. J. Glaucoma 5 (1996) 427-432
75. Shaked I., Tchroesh D., Gersner R., Meiri G., Mordechai S., Xiao X., Hart R.P., and Schwartz M. Protective autoimmunity: interferon-gamma enables microglia to remove glutamate without evoking inflammatory mediators. J. Neurochem. 92 (2005) 997-1009
76. Sigal I.A., Flanagan J.G., and Ethier C.R. Factors influencing optic nerve head biomechanics. Invest. Ophthalmol. Vis. Sci. 46 (2005) 4189-4199
77. Siliprandi R., Canella R., Carmignoto G., Schiavo N., Zanellato A., Zanoni R., and Vantini G. N-Methyl-d-aspartate-induced neurotoxicity in the adult rat retina. Vis. Neurosci. 8 (1992) 567-573
78. Siu A.W., Maldonado M., Sanchez-Hidalgo M., Tan D.X., and Reiter R.J. Protective effects of melatonin in experimental free radical-related ocular diseases. J. Pineal Res. 40 (2006) 101-109
79. Stuiver B.T., Douma B.R., Bakker R., Nyakas C., and Luiten P.G. In vivo protection against NMDA-induced neurodegeneration by MK-801 and nimodipine: combined therapy and temporal course of protection. Neurodegeneration 5 (1996) 153-159
80. Sucher N.J., Lipton S.A., and Dreyer E.B. Molecular basis of glutamate toxicity in retinal ganglion cells. Vision Res. 37 (1997) 3483-3493
81. Sultana R., Poon H.F., Cai J., Pierce W.M., Merchant M., Klein J.B., Markesbery W.R., and Butterfield D.A. Identification of nitrated proteins in Alzheimer's disease brain using a redox proteomics approach. Neurobiol. Dis. 22 (2006) 76-87
82. Takahashi K., Lam T.T., Edward D.P., Buchi E.R., and Tso M.O. Protective effects of flunarizine on ischemic injury in the rat retina. Arch. Ophthalmol. 110 (1992) 862-870
83. Tezel G. Oxidative stress in glaucomatous neurodegeneration: mechanisms and consequences. Prog. Retin. Eye Res. 25 (2006) 490-513
84. Tezel G., Hernandez R., and Wax M.B. Immunostaining of heat shock proteins in the retina and optic nerve head of normal and glaucomatous eyes. Arch. Ophthalmol. 118 (2000) 511-518
85. Tezel G., and Wax M.B. Glial modulation of retinal ganglion cell death in glaucoma. J. Glaucoma 12 (2003) 63-68
86. Tezel G., and Wax M.B. Hypoxia-inducible factor 1alpha in the glaucomatous retina and optic nerve head. Arch. Ophthalmol. 122 (2004) 1348-1356
87. Tezel G., Yang X., and Cai J. Proteomic identification of oxidatively modified retinal proteins in a chronic pressure-induced rat model of glaucoma. Invest. Ophthalmol. Vis. Sci. 46 (2005) 3177-3187
88. Thornberry N.A. Caspases: key mediators of apoptosis. Chem. Biol. 5 (1998) R97-R103
89. Thornberry N.A., and Lazebnik Y. Caspases: enemies within. Science 281 (1998) 1312-1316
90. Tsacopoulos M., Poitry-Yamate C.L., MacLeish P.R., and Poitry S. Trafficking of molecules and metabolic signals in the retina. Prog. Retin. Eye Res. 17 (1998) 429-442
91. Unoki K., and LaVail M.M. Protection of the rat retina from ischemic injury by brain-derived neurotrophic factor, ciliary neurotrophic factor, and basic fibroblast growth factor. Invest. Ophthalmol. Vis. Sci. 35 (1994) 907-915
92. Van Den Bosch L., Van Damme P., Bogaert E., and Robberecht W. The role of excitotoxicity in the pathogenesis of amyotrophic lateral sclerosis. Biochim. Biophys. Acta 1762 (2006) 1068-1082
93. Weinreb R.N., and Khaw P.T. Primary open-angle glaucoma. Lancet 363 (2004) 1711-1720
94. Weydt P., and La Spada A.R. Targeting protein aggregation in neurodegeneration - lessons from polyglutamine disorders. Expert Opin. Ther. Targets 10 (2006) 505-513
95. Yoles E., Hauben E., Palgi O., Agranov E., Gothilf A., Cohen A., Kuchroo V., Cohen I.R., Weiner H., and Schwartz M. Protective autoimmunity is a physiological response to CNS trauma. J. Neurosci. 21 (2001) 3740-3748